OsteoBiologics Inc.
This article was originally published in Start Up
Executive Summary
Until recently, there were no treatments to replace damaged cartilage. OsteoBiologics Inc., spun out of technology licensed from the University of Texas Health Science Center, has developed a resorbable biopolymer that may stand alone to mechanically replace damaged cartilage, or may serve as a biologically friendly scaffolding for cell therapies and techniques involving growth factors.
You may also be interested in...
Biomaterials: Mechanical Engineering Meets Biology
Start-ups developing man-made surrogates for living processes hope to achieve the alchemy of turning base materials into human tissue.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.